Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status

Blood (2022) 140 (Supplement 1): 8524–8525.

https://doi.org/10.1182/blood-2022-170581

Published: 2022

Journal Articles

Blood Biomarkers for the Prediction of Venous Thromboembolism in Perioperative or Hospitalized Cancer Patients: A Systematic Review

Danielle Carole Roy, Amin Zahrai, Ronda Lun, Tzu-Fei Wang, Steven Hawken, Ranjeeta Mallick, Dylan Burger, Philip S. Wells

Blood (2022) 140 (Supplement 1): 5700–5701.

https://doi.org/10.1182/blood-2022-159792

Published: 2022

Journal Articles

Thrombophilia Gene Mutations for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy

Danielle Carole Roy, Tzu-Fei Wang, Ranjeeta Mallick, Philip S. Wells, Marc Carrier, Steven Hawken

Blood (2022) 140 (Supplement 1): 2792–2793.

https://doi.org/10.1182/blood-2022-160158

Published: 2022

Journal Articles

A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3

Michael J. Kovacs, Philip S. Wells, Marc A. Rodger, Marc Carrier, Erik Yeo, Judy A Kovacs, Alejandro Lazo-Langner

Blood (2022) 140 (Supplement 1): 1245–1246.

https://doi.org/10.1182/blood-2022-159135

Published: 2022

Journal Articles

Safety and Efficacy of Apixaban Thromboprophylaxis in Ambulatory Cancer Patients By Renal Function: A Subgroup Analysis of the Avert Trial

Tzu-Fei Wang, Ranjeeta Mallick, Marc Carrier, Philip S. Wells

Blood (2021) 138 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2021-149681

Published: 2021

Journal Articles

Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis

Allen Li, Willem Brandt, Cameron Brown, Tzu-Fei Wang, Rick Ikesaka, Aurelien Delluc, Philip S. Wells, Marc Carrier

Blood (2021) 138 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2021-146904

Published: 2021

Journal Articles

Efficacy and Safety of Apixaban for Primary Prevention of Thromboembolism in Cancer Patients with a Newly Inserted Central Venous Catheter: A Post-Hoc Analysis of the Avert Trial

Willem Brandt, Cameron Brown, Amin Zahrai, Ranjeeta Mallick, Philip S. Wells, Marc Carrier

Blood (2021) 138 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2021-148683

Published: 2021

Journal Articles

Apixaban Anti-Xa Level Monitoring in Treatment of Provoked Acute Upper Extremity Deep Vein Thrombosis for Patient on Dialysis: A Case Report

Guillaume Roberge, MD, Philip S. Wells, MDMSc,FRCP

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-141911

Published: 2020

Journal Articles

Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer

Joseph R. Shaw, MD, Ranjeeta Mallick, PhD MSc, BSc, Marc Carrier, MD, Anton Ilich, MD, Nigel S. Key, MBChB, FRCP, Philip S. Wells, MDMSc,FRCP

Blood (2019) 134 (Supplement_1): 634.

https://doi.org/10.1182/blood-2019-126306

Published: 2019

Journal Articles

Thromboprophylaxis for Patients with Newly Diagnosed Vs. Recurrent Cancers: A Post-Hoc Analysis of the Avert Trial

Marina Atalla, James Zhang, MD, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD

Blood (2019) 134 (Supplement_1): 3660.

https://doi.org/10.1182/blood-2019-122970

Published: 2019

Journal Articles

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

William Knoll, BSc, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD

Blood (2019) 134 (Supplement_1): 1140.

https://doi.org/10.1182/blood-2019-128834

Published: 2019

Journal Articles

Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy

Miriam Kimpton, MD, Srishti Kumar, MSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD, Kednapa Thavorn, MPharm, PhD

Blood (2019) 134 (Supplement_1): 329.

https://doi.org/10.1182/blood-2019-127286

Published: 2019

Journal Articles

Evaluation of Definitions for Oral Anticoagulant–Associated Major Bleeding: A Population-Based Cohort Study

Yan Xu, MD, Tara Gomes, PhD MHSc, Philip S. Wells, MDMSc,FRCP, Ana Johnson, PhD, Michelle Sholzberg, MD

Blood (2018) 132 (Supplement 1): 426.

https://doi.org/10.1182/blood-2018-99-111207

Published: 2018

Journal Articles

Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

Michael J. Kovacs, MD, Marc Rodger, MDMSc, Philip S. Wells, MDMSc,FRCP, Shannon M. Bates, MD MSc, Clive Kearon, MB, PhD, Mark Blostein, MDFRCPC, Alejandro Lazo-Langner, MD MSc, Susan Kahn, MD, Sam Schulman, MD PhD FRCPC, Elham Sabri, MSc, Susan Solymoss, MD, Timothy Ramsay, PhD, Luljeta Pallaveshi, RN, BA, David Anderson, MD

Blood (2018) 132 (Supplement 1): 424.

https://doi.org/10.1182/blood-2018-99-109964

Published: 2018

Journal Articles

DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis

Cavin K. Ward-Caviness, Jennifer E. Huffman, Karl Everett, Marine Germain, Jenny van Dongen, W. David Hill, Min A. Jhun, Jennifer A. Brody, Mohsen Ghanbari, Lei Du, Nicholas S. Roetker, Paul S. de Vries, Melanie Waldenberger, Christian Gieger, Petra Wolf, Holger Prokisch, Wolfgang Koenig, Christopher J. O’Donnell, Daniel Levy, Chunyu Liu, Vinh Truong, Philip S. Wells, David-Alexandre Trégouët, Weihong Tang, Alanna C. Morrison, Eric Boerwinkle, Kerri L. Wiggins, Barbara McKnight, Xiuqing Guo, Bruce M. Psaty, Nona Sotoodehnia, Dorret I. Boomsma, Gonneke Willemsen, Lannie Ligthart, Ian J. Deary, Wei Zhao, Erin B. Ware, Sharon L. R. Kardia, Joyce B. J. Van Meurs, Andre G. Uitterlinden, Oscar H. Franco, Per Eriksson, Anders Franco-Cereceda, James S. Pankow, Andrew D. Johnson, France Gagnon, Pierre-Emmanuel Morange, Eco J. C. de Geus, John M. Starr, Jennifer A. Smith, Abbas Dehghan, Hanna M. Björck, Nicholas L. Smith, Annette Peters

Blood (2018) 132 (17): 1842–1850.

https://doi.org/10.1182/blood-2018-02-831347

Published: 2018

Includes: Supplemental data

Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD

Blood (2017) 130 (Supplement 1): 218.

https://doi.org/10.1182/blood.V130.Suppl_1.218.218

Published: 2017

Journal Articles

Evidence-Based Diagnosis of Venous Thromboembolism: A Systematic Review

Ryma Ihaddadene, BHSc, MSc, Melissa Anne Forgie, MD FRCPC, MSc, BA, Philip S. Wells, MD FRCPC, MSc

Blood (2017) 130 (Supplement 1): 2082.

https://doi.org/10.1182/blood.V130.Suppl_1.2082.2082

Published: 2017

Journal Articles

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Alok A. Khorana, MD, Jeffrey S Berger, MD, Philip S Wells, MD, Roger Seheult, MD, Veronica Ashton, MPH, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Dominique Lejeune, MA, Jeff Schein, DrPH, MPH, Peter Wildgoose, PhD, Patrick Lefebvre, MA, Scott Kaatz, DO, MSc

Blood (2016) 128 (22): 144.

https://doi.org/10.1182/blood.V128.22.144.144

Published: 2016

Journal Articles

Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism

Philip S Wells, MD, Michael J. Kovacs, MD FRCPC, David Anderson, MD, Susan R. Kahn, MD, Clive Kearon, MB, Sam Schulman, MD PhD FRCPC, David M. Keeling, MD, Scott Kaatz, DO, MSc, Susan Solymoss, MD, Daniel Corsi, PhD, Marc Rodger, MD MSc, FRCPC

Blood (2016) 128 (22): 139.

https://doi.org/10.1182/blood.V128.22.139.139

Published: 2016

Journal Articles

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

Neela K Kumar, MSPH, Erin R Weeda, PharmD, Philip S Wells, MD, Frank Peacock, MD, Gregory J Fermann, MD, Li Wang, MA, PhD MBA, Onur Baser, MS, PhD, Jeff Schein, DrPH, MPH, Crivera Crivera, PharmD, MPH, Craig I Coleman, PharmD, Christine G Kohn, PharmD

Blood (2016) 128 (22): 533.

https://doi.org/10.1182/blood.V128.22.533.533

Published: 2016

NARROW

Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status

Blood Biomarkers for the Prediction of Venous Thromboembolism in Perioperative or Hospitalized Cancer Patients: A Systematic Review

Thrombophilia Gene Mutations for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy

A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3

Safety and Efficacy of Apixaban Thromboprophylaxis in Ambulatory Cancer Patients By Renal Function: A Subgroup Analysis of the Avert Trial

Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis

Efficacy and Safety of Apixaban for Primary Prevention of Thromboembolism in Cancer Patients with a Newly Inserted Central Venous Catheter: A Post-Hoc Analysis of the Avert Trial

Apixaban Anti-Xa Level Monitoring in Treatment of Provoked Acute Upper Extremity Deep Vein Thrombosis for Patient on Dialysis: A Case Report

Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer

Thromboprophylaxis for Patients with Newly Diagnosed Vs. Recurrent Cancers: A Post-Hoc Analysis of the Avert Trial

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy

Evaluation of Definitions for Oral Anticoagulant–Associated Major Bleeding: A Population-Based Cohort Study

Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Evidence-Based Diagnosis of Venous Thromboembolism: A Systematic Review

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only